A randomized, controlled trial of omega-3 fatty acids plus an antioxidant for relapse prevention after antipsychotic discontinuation in first-episode schizophrenia
Background While antipsychotics are effective in the maintenance treatment of
schizophrenia they have safety and tolerability risks. We investigated whether a combination …
schizophrenia they have safety and tolerability risks. We investigated whether a combination …
[HTML][HTML] Randomized, placebo-controlled clinical trial of omega-3 as supplemental treatment in schizophrenia
H Jamilian, H Solhi, M Jamilian - Global journal of health science, 2014 - ncbi.nlm.nih.gov
Conclusion: We found that supplemental omega-3 might increase efficacy of conventional
antipsychotics in decreasing symptoms of schizophrenia. Low price, rare adverse reactions …
antipsychotics in decreasing symptoms of schizophrenia. Low price, rare adverse reactions …
Treatment of neurolept-induced tardive dyskinesia
SK Jankelowitz - Neuropsychiatric disease and treatment, 2013 - Taylor & Francis
Tardive dyskinesia (TDK) includes orobuccolingual movements and “piano-playing”
movements of the limbs. It is a movement disorder of delayed onset that can occur in the …
movements of the limbs. It is a movement disorder of delayed onset that can occur in the …
[图书][B] Managing the side effects of psychotropic medications
JF Goldberg, CL Ernst - 2018 - books.google.com
" This book has been divided into three main sections. Part I deals with global issues that
bear on the assessment and formulation of possible adverse effects and with pertinent …
bear on the assessment and formulation of possible adverse effects and with pertinent …
Omega-3 fatty acids in first-episode schizophrenia-a randomized controlled study of efficacy and relapse prevention (OFFER): rationale, design, and methods
T Pawełczyk, M Grancow, M Kotlicka-Antczak… - BMC psychiatry, 2015 - Springer
Background Polyunsaturated fatty acid (PUFA) metabolism abnormalities have been long
implicated in the etiology of schizophrenia. Although several randomized clinical trials have …
implicated in the etiology of schizophrenia. Although several randomized clinical trials have …
Systematic review of interventions for treating or preventing antipsychotic-induced tardive dyskinesia.
H Bergman, DM Walker, A Nikolakopoulou… - Health technology …, 2017 - boris.unibe.ch
BACKGROUND Antipsychotic medication can cause tardive dyskinesia (TD)-late-onset,
involuntary, repetitive movements, often involving the face and tongue. TD occurs in> 20% of …
involuntary, repetitive movements, often involving the face and tongue. TD occurs in> 20% of …
Effects of Omega-3 in the treatment of violent schizophrenia patients
Y Qiao, Y Mei, H Han, FJ Liu, XM Yang, Y Shao… - Schizophrenia …, 2018 - Elsevier
Objective: This study was designed to explore the relationship in between the daily
consumption of fish oil (360 mg DHA+ 540 mg EPA), and reduction of symptoms and violent …
consumption of fish oil (360 mg DHA+ 540 mg EPA), and reduction of symptoms and violent …
Effects of omega 3 fatty acids on main dimensions of psychopathology
P Bozzatello, ML De Rosa, P Rocca… - International journal of …, 2020 - mdpi.com
The usefulness of polyunsaturated fatty acids on inflammatory, cardiovascular, and the
nervous system was studied in the last decades, but the mechanisms underlying their …
nervous system was studied in the last decades, but the mechanisms underlying their …
Omega-3 fatty acid eicosapentaenoic acid. A new treatment for psychiatric and neurodegenerative diseases: a review of clinical investigations
C Song, S Zhao - Expert opinion on investigational drugs, 2007 - Taylor & Francis
Decreased n-3 fatty acid levels have been reported in patients with depression,
schizophrenia or Alzheimer's disease. Recently, eicosapentaenoic acid (EPA) has been …
schizophrenia or Alzheimer's disease. Recently, eicosapentaenoic acid (EPA) has been …
Drug repurposing and emerging adjunctive treatments for schizophrenia
Introduction: Schizophrenia is a frequent disorder, which substantially impairs patients'
quality of life. Moreover, the burden of illness for patients, their families and for the society, in …
quality of life. Moreover, the burden of illness for patients, their families and for the society, in …